{"title":"In Vitro Investigation of Potential Pepsin Inhibitors: New Perspectives for the Treatment of Gastroesophageal Reflux","authors":"L. Leoni, V. Damiani, R. Salvio","doi":"10.2174/1573408018666220307121130","DOIUrl":null,"url":null,"abstract":"\n\nIn patients with Gastroesophageal Reflux (GER), the digestive enzyme pepsin can reach the esophagus and extraesophageal sites and cause damages with the appearance of inflammation and other tedious symptoms.\n\n\n\nIn this work, a number of biocompatible, non-toxic and hypoallergenic compounds were tested in vitro as inhibitors of pepsin. The residual enzyme activity in the presence of the investigated compounds was measured through a convenient and reliable UV-vis method based on the cleavage of hemoglobin. This method is applicable even if the investigated additives are scarcely soluble in water and the test mixtures are dispersions rather than solutions.\n\n\n\nA few negatively charged saccharides showed the highest effect among the investigated compounds. The inhibitory activity of pepstatin and lovastatin was also tested with the same method in a wide range of concentrations. These compounds turned out to be effective even if present in extremely low amount. A docking and molecular dynamic investigation provides useful insights about the binding site and the mechanism of action of pepstatin as inactivating agent towards pepsin.\n\n\n\nIn particular, the computational study indicates that the binding with this compound significantly increases the mobility of the active site residues and prevent them from cooperate in the reactive event.\n","PeriodicalId":35405,"journal":{"name":"Current Enzyme Inhibition","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2022-03-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Enzyme Inhibition","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/1573408018666220307121130","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}
引用次数: 0
Abstract
In patients with Gastroesophageal Reflux (GER), the digestive enzyme pepsin can reach the esophagus and extraesophageal sites and cause damages with the appearance of inflammation and other tedious symptoms.
In this work, a number of biocompatible, non-toxic and hypoallergenic compounds were tested in vitro as inhibitors of pepsin. The residual enzyme activity in the presence of the investigated compounds was measured through a convenient and reliable UV-vis method based on the cleavage of hemoglobin. This method is applicable even if the investigated additives are scarcely soluble in water and the test mixtures are dispersions rather than solutions.
A few negatively charged saccharides showed the highest effect among the investigated compounds. The inhibitory activity of pepstatin and lovastatin was also tested with the same method in a wide range of concentrations. These compounds turned out to be effective even if present in extremely low amount. A docking and molecular dynamic investigation provides useful insights about the binding site and the mechanism of action of pepstatin as inactivating agent towards pepsin.
In particular, the computational study indicates that the binding with this compound significantly increases the mobility of the active site residues and prevent them from cooperate in the reactive event.
期刊介绍:
Current Enzyme Inhibition aims to publish all the latest and outstanding developments in enzyme inhibition studies with regards to the mechanisms of inhibitory processes of enzymes, recognition of active sites, and the discovery of agonists and antagonists, leading to the design and development of new drugs of significant therapeutic value. Each issue contains a series of timely, in-depth reviews written by leaders in the field, covering a range of enzymes that can be exploited for drug development. Current Enzyme Inhibition is an essential journal for every pharmaceutical and medicinal chemist who wishes to have up-to-date knowledge about each and every development in the study of enzyme inhibition.